Metabolic regulation by the intestinal metformin-AMPK axis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35606343.
- Also identified by DOI 10.1038/s41467-022-30477-3 and PMC identifier 9126964.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
AMP-activated protein kinase (AMPK) mediates the glucose-lowering effect of the antidiabetic agent metformin, but the sites of action remain unclear. In the March issue of Nature Communications, Zhang and colleagues reported that intestinal epithelium-specific AMPKα1 knockout mice fail to respond to metformin and exhibit disruption in metabolic homeostasis secondary to changes in the gut microbiome. This highlights a therapeutic potential of targeting intestinal AMPK for diabetes.
Medical subject headings
- Diabetes Mellitus, Type 2
- Metformin